Tel.: 514-340-8222 ext. 28394
Administrative Assistant:
Melissa Dahan
Centre For Clinical Epidemiology
Jewish General Hospital - Lady Davis Institute
3755 Cote Ste-Catherine, Suite H-485
Montreal, Quebec H3T 1E2 Canada 
Tel.: 514-340-8222, ext. 24561
Fax: 514-340-7564
Kristian B. Filion, PhD, FAHA
Associate Professor, Department of Medicine and Department of Epidemiology, Biostatistics, and Occupational Health, McGill University
Investigator, Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital
Dr. Filion is an Associate Professor in the Departments of Medicine (Division of Clinical Epidemiology) and of Epidemiology, Biostatistics, and Occupational Health at McGill University and a Principal Investigator at the Center for Clinical Epidemiology of the Lady Davis Institute. He obtained his PhD in Epidemiology from McGill's Department of Epidemiology, Biostatistics, and Occupational Health and completed his post-doctoral training in Cardiovascular Epidemiology at the Division of Epidemiology and Community Health of the University of Minnesota.
Major Research Activities
Dr. Filion's research interests include pharmacoepidemiology and drug safety, knowledge synthesis, and cardiovascular epidemiology. He uses large, population-based databases to study the safety of commonly prescribed medications, with a particular interest in cardiovascular medications and cardiovascular outcomes. He is the Co-Lead of the Clinical Practice Research Datalink (CPRD) Team of the Canadian Network for Observational Drug Effect Studies (CNODES), a pan-Canadian drug safety network funded by the Canadian Institutes of Health Research. In addition, Dr. Filion is involved in a number of systematic reviews and meta-analyses examining the efficacy and safety of cardiovascular therapies.

Recent Publications 
Filion KB, Azoulay L, Platt RW, Dahl M, Dormuth CR, Clemens KK, Hu N, Paterson JM, Targownik L, Turin TC, Udell JA, Ernst P for the Canadian Network for Observational Drug Effect Studies (CNODES) Investigators. A multicenter observational study of incretin-based drugs and heart failure. N Engl J Med 2016; 374:1145-54. [Press release]
Secrest MH, Platt RW, Dormuth CR, Chateau D, Targownik L, Nie R, Doyle CM, Dell'Aniello S, Filion KB. Extreme restriction design as a method for reducing confounding by indication in pharmacoepidemiologic research. Pharmacoepidemiol Drug Saf. 2019 Jan 9. doi: 10.1002/pds.4708

Eberg M, Platt RW, Filion KB. The estimation of gestational age at birth in database studies. Epidemiology. 2017;28:854-862.

Dr. Filion is an epidemiologist who leads an active research program in cardiovascular epidemiology, pharmacoepidemiology, and drug safety.

Dr. Filion is supported by a chercheur-boursier Junior II salary support award from the Fonds de recherche du Québec – santé and a William Dawson Scholar award from McGill University. 
Important Links

Support research at the Lady Davis Institute - Jewish General Hospital